Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
Previous Story
Global Bond Sell-Off Puts Investors on Edge
Next Story
At G20 Meeting, Scott Bessent Accuses China of Flooding the World With Cheap Exports
